

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6838191

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
AICURIS ANTI-INFECTIVE CURES GMBH	04/12/2021
RECEIVING PARTY DATA	
Name:	AICURIS ANTI-INFECTIVE CURES AG
Street Address:	FRIEDRICH-EBERT-STR. 475
City:	WUPPERTAL
State/Country:	GERMANY
Postal Code:	42117
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17320587
CORRESPONDENCE DATA	
Fax Number:	(703)243-6410
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-243-6333
Email:	mail@mwzb.com
Correspondent Name:	TIMIKA SNOWDEN
Address Line 1:	C/O MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Address Line 2:	2200 CLARENDON BLVD., SUITE 1400
Address Line 4:	ARLINGTON, VIRGINIA 22201
ATTORNEY DOCKET NUMBER:	BOEHMERP-0212-D01-RE
NAME OF SUBMITTER:	TIMIKA SNOWDEN
SIGNATURE:	/Timika Snowden/
DATE SIGNED:	07/29/2021
Total Attachments: 7	
source=CommercialRegisterBoftheWuppertalLocalCourt#page1.tif	
source=CommercialRegisterBoftheWuppertalLocalCourt#page2.tif	
source=MunicipalCourtWuppertal_FileNo_HRB_31630#page1.tif	
source=Translation_MunicipalCourtWuppertal_FileNo_HRB_31630#page1.tif	
source=Translation_MunicipalCourtWuppertal_FileNo_HRB_31630#page2.tif	

source=Translation_MunicipalCourtWuppertal_FileNo_HRB_31630#page3.tif

source=Translation_MunicipalCourtWuppertal_FileNo_HRB_31630#page4.tif

Commercial Register B of the Wuppertal Local Court	Department B Reproduction of the current content of the register Retrieved on 07/16/2021 (16 July 2021) 07:29 a.m.	Company number: HRB 31630
Reprint	Page 1 of 2	

1. Number of previous entries:

7

2. a) Company:

AiCuris Anti-infective Cures AG

b) Registered office, establishment, domestic business address, branches:

Wuppertal

Business address: Friedrich-Ebert-Strasse 475, 42117 Wuppertal

c) Purpose of the company:

Research and development, marketing and manufacture of products, provision of services and other industrial activities in the field of health, in particular for development, marketing and manufacture of new drugs and therapies to prevent or treat infectious diseases.

3. Nominal capital / capital stock:

15.000.001,00 EUR

4. a) General rules of representation:

If only one member of the Management Board is appointed, he/she represents the company alone. If a plurality of board members is appointed, two of the board members together or one board member together with an authorized officer (procurator) represent the company.

b) Board of Directors, management body, managing directors, personally liable partners, business executives, authorized representatives and special powers of representation:

Authorized to represent together with another board member or an authorized officer with the authority to conclude legal transactions on behalf of the company as a representative of a third party:

Managing Director: Schmoll, Holger, Wuppertal, * July 15, 1966

Managing Director: Dr. Zimmermann, Holger, Wuppertal, * December 4th, 1968

5. Authorized Officer (procurator):

Joint authorization together with a member of the Management Board with the authority to conclude legal transactions on behalf of the company as a representative of a third party:

van Dyken, Gerrit, Düsseldorf, * June 18, 1966

6. a) Legal form, start and statutes:

Stock corporation

Statute of January 28, 2021

Last changed by resolution on May 18, 2021

Commercial Register B of the Wuppertal Local Court	Department B Reproduction of the current content of the register Retrieved on 07/16/2021 (16 July 2021) 07:29 a.m.	Company number: HRB 31630
Reprint	Page 2 of 2	

b) Other legal relationships:

By resolution of January 28, 2021 pursuant to Section 4 (6) of the Statute, the nominal capital is conditionally increased by up to EUR 1,500,000.00 to service purchase warrants derived from stock options granted until January 27, 2026 based on the authorization granted by the resolution of January 28, 2021 (Conditional Capital 2021 / I).

By resolution of January 28, 2021 pursuant to Section 4 (7) of the Statute, the nominal capital is conditionally increased by up to EUR 6,000,000.00 to grant shares to holders of bonds with warrants and convertible bonds, based on the authorization granted by the resolution of January 28, 2021 (Conditional Capital 2021 / II).

The Management Board is authorized by Section 4 (5) of the Statute of January 28, 2021 to increase the nominal capital, with the approval of the Supervisory Board, until January 27, 2026 by issuing new shares for cash or non-cash contributions once or several times for a total of up to EUR 7,500,000.00. The purchase right of the shareholders can be excluded (Approved Capital 2021 / I).

7. a) Date of the last entry:

07/09/2021 (9 July 2021)

In () gesetzte Angaben der Anschrift und des Geschäftszweiges erfolgen ohne Gewähr.

Neueintragungen

12.04.2021

HRB 31630: AiCuris Anti-Infective Cures AG, Wuppertal, Friedrich-Ebert-Straße 475, Gebäude 302, 42117 Wuppertal. Aktiengesellschaft. Satzung vom 28.01./08.04.2021. Geschäftsanschrift: Friedrich-Ebert-Straße 475, Gebäude 302, 42117 Wuppertal. Gegenstand: Die Forschung und Entwicklung, die Vermarktung und Herstellung von Produkten, die Erbringung von Dienstleistungen und die sonstige industrielle Betätigung auf dem Gebiet der Gesundheit, insbesondere zur Entwicklung, Vermarktung und Herstellung neuer Medikamente und Therapien zur Verhinderung oder Behandlung von Infektionskrankheiten. Grundkapital: 15.000.000,00 EUR. Allgemeine Vertretungsregelung: Ist nur ein Vorstandsmitglied bestellt, so vertritt es die Gesellschaft allein. Sind mehrere Vorstandsmitglieder bestellt, so wird die Gesellschaft durch zwei Vorstandsmitglieder oder durch ein Vorstandsmitglied gemeinsam mit einem Prokuristen vertreten. Vorstand: Schmoll, Holger, Wuppertal, *15.07.1966; Dr. Zimmermann, Holger, Wuppertal, *04.12.1968, jeweils vertretungsberechtigt gemeinsam mit einem anderen Vorstandsmitglied oder einem Prokuristen mit der Befugnis im Namen der Gesellschaft mit sich als Vertreter eines Dritten Rechtsgeschäfte abzuschließen. Entstanden durch Umwandlung im Wege des Formwechsels der AiCuris Anti-Infective Cures GmbH, Wuppertal (HRB 26180) nach Maßgabe des Beschlusses der Gesellschafterversammlung vom 28.01.2021. Der Vorstand ist durch § 4 Abs. 5 der Satzung vom 28.01.2021 ermächtigt, das Grundkapital mit Zustimmung des Aufsichtsrates bis zum 27.01.2026 durch Ausgabe neuer Aktien gegen Bar- oder Sacheinlagen einmal oder mehrmals um insgesamt bis zu EUR 7.500.000,00 zu erhöhen. Das Bezugsrecht der Aktionäre kann ausgeschlossen werden (Genehmigtes Kapital 2021/I). Das Grundkapital ist durch Beschluss vom 28.01.2021 gemäß § 4 Abs. 6 der Satzung um bis zu EUR 1.500.000,00 zur Bedienung von Bezugsrechten aus Aktienoptionen, die aufgrund der Ermächtigung durch den Beschluss vom 28.01.2021 bis zum 27.01.2026 gewährt wurden, bedingt erhöht (Bedingtes Kapital 2021/I). Das Grundkapital ist durch Beschluss vom 28.01.2021 gemäß § 4 Abs. 7 der Satzung um bis zu EUR 6.00.000,00 zur Gewährung von Aktien an Inhaber von Optionsschuldverschreibungen und Wandelschuldverschreibungen, die aufgrund der Ermächtigung durch den Beschluss vom 28.01.2021 bis zum 27.01.2026 gewährt wurden, bedingt erhöht (Bedingtes Kapital 2021/II). Als nicht eingetragen wird bekannt gemacht: Den Gläubigern der an der formwechselnden Umwandlung beteiligten Rechtsträger ist, wenn sie binnen sechs Monaten nach dem Tag, an dem die Eintragung der formwechselnden Umwandlung in das Register des Sitzes desjenigen Rechtsträgers, dessen Gläubiger sie sind, nach § 19 Absatz 3 UmwG als bekanntgemacht gilt, ihren Anspruch nach Grund und Höhe schriftlich anmelden, Sicherheit zu leisten, soweit sie nicht Befriedigung verlangen können. Dieses Recht steht den Gläubigern jedoch nur zu, wenn sie glaubhaft machen, dass durch die formwechselnden Umwandlung die Erfüllung ihrer Forderung gefährdet wird.

VERIFICATION OF TRANSLATION

I, Melissa Stanford, a translator with Chillson Translating Service, 3530 Chas Drive, Hampstead, Maryland, 21074, hereby declare as follows:

That I am familiar with the German and English languages;

That I am capable of translating from German to English;

That the translation attached hereto is a true and accurate translation of German language document Ref: Municipal Court of Wuppertal, File No.: HRB 31630;

That all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true;

And further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any registration resulting therefrom.

By Melissa Stanford

Executed this 22 day of July 2021

Witness James Hillis

Translator's Note:

On line 11 from the bottom of the German text, the amount of Euros was erroneously cited as "6.00.000,00," which equates to the anglicized form, also erroneous, of "6,00,000.00"

[English page 2, line 8].

Municipal Court of Wuppertal, File No.: HRB 31630 Announced on 04/12/2021 2000 hours

No guarantee is given for the correctness of the information regarding the address and line of business given in parentheses.

New Registrations

04/12/2021

HRB 31630: AiCuris Anti-Infective Cures AG, Wuppertal, Friedrich-Ebert-Straße 475, Gebäude 302, 42117 Wuppertal. Limited Company. Bylaws dated 01/28//04/08/2021. Business address: Friedrich-Ebert-Straße 475, Gebäude 302, 42117 Wuppertal. Object: The research and development, the marketing and production of products, provision of services, and the other industrial operation in the health field, in particular for development, marketing, and production of new medications and therapies for preventing or treating infectious diseases. Corporate capital: 15,000,000.00 Euros. General provisions on representation: If only one board member is appointed, he shall be the sole representative of the company. If multiple board members are appointed, the company shall be represented by two board members or by one board member together with a fully authorized officer. Executive Board: Schmoll, Holger, Wuppertal, *07/15/1966; Dr. Zimmermann, Holger, Wuppertal, *12/04/1968, in each case authorized to complete transactions together with another board member or a fully authorized officer with the power, on behalf of the company as a representative of a third party. Creation by conversion by change of form of the AiCuris Anti-Infective Cures GmbH, Wuppertal (HRB 26180) according to the provisions of the resolution of the shareholders' meeting on 01/28/2021. The Executive Board shall be authorized by §4, paragraph 5 of the Bylaws dated 01/28/2021 to increase the corporate capital one or more times by a total of up to 7,500,000.00 Euros with the consent of the

Board of Directors by 01/27/2026 by issuing new shares against cash contributions or contributions in kind. There are no purchase rights for the shareholders (authorized capital 2021/I). The corporate capital is conditionally increased (potential capital 2021/I) by the resolution dated 01/28/2021 according to §4, paragraph 6 of the Bylaws by up to 1,500,000.00 Euros for service of purchase rights from share options that were granted based on the authorization by the resolution dated 01/28/2021 to 01/27/2026. The corporate capital is conditionally increased (potential capital 2021/II) by the resolution dated 01/28/2021 according to §4, paragraph 7 of the Bylaws by up to 6,00,000.00 [sic] Euros to grant shares to holders of warrant bonds and convertible bonds, which were granted based on the authorization by the resolution dated 01/28/2021 to 01/27/2026. The following is announced as not recorded: to the extent that they are unable to demand payoff, collateral shall be extended to the creditors of the legal entities involved in the form-changing conversion, provided that said creditors submit their claims, stating basis and amounts, within six months of the date when the recording of the form-changing conversion in the Register of the place of business of this legal entity with which they are creditors is considered announced according to §19, paragraph 3 of the UmwG [Conversion Act]. The creditors shall be entitled to the right, however, only if they substantiate that the form-changing conversion jeopardizes the fulfillment of their claims.